Anti-aging
Anti-aging menus use many names. What stem cell treatments, exosomes, PRP and NAD+ are, how each is regulated in Japan, and what to watch for in the marketing.
01What this topic covers
- Stem cell anti-aging treatments
- Exosomes
- PRP
- NAD+
- Reading anti-aging claims
02Which class it generally falls into in Japan
- iPS cells, ES cells and similar: generally Class I (high risk).
- The patient’s own somatic stem cells (e.g. adipose-derived stem cells): generally Class II (medium risk).
- Somatic cell processing without stem cells (e.g. immune cell therapy): generally Class III (low risk).
- PRP depends on how it is used: injection into a joint or other “non-homologous use” is Class II (medium risk); dental and similar uses are mostly Class III.
This is how treatments generally map; the class of a specific treatment is whatever the clinic’s submitted plan states.
For exosomes, NAD+ and other treatments outside these common mappings, send the treatment and clinic names to an advisor and we will check them with you.
Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); MHLW division notice, risk-classification chart; checked 2026-11
03Guides in this topic
Guides are on the way
Guides for this topic are being prepared, each with its sources and the date it was checked. Meanwhile, start with these pages.